Management
Among 52,588 hip arthroplasty patients, those treated with rifampicin (n=20) showed no significant difference in revision arthroplasty rates compared to those without rifampicin (n=33) [PMID:40396698].
Two-stage reconstruction using AHAB showed 100% clinical success in treating 20 PJI and 7 SA patients over a mean follow-up of 37 months [PMID:25800641].
In vitro studies demonstrated that AHAB released active vancomycin for 21 days with higher amounts compared to ALAC, which lasted only 7 days [PMID:25800641].
Complications
The study found no significant difference in adverse events between patients treated with and without rifampicin [PMID:40396698].
Prognosis & Follow-up
Given the similar outcomes and safety profiles, close monitoring remains crucial for patients receiving rifampicin combination therapy [PMID:40396698].
The study reported significant improvement in hip function and no recurrence of infection in patients treated with AHAB over a mean follow-up period of 37 months [PMID:25800641].
References
1 Nitta A, Goda M, Niimura T, Kajihara T, Sato M, Chuma M et al.. Rifampicin in combination treatments for methicillin-resistant staphylococcal prosthetic joint infections: Claims database evaluation using a cohort of 52,588 hip arthroplasty patients. International journal of clinical pharmacology and therapeutics 2025. link 2 Choe H, Inaba Y, Kobayashi N, Miyamae Y, Ike H, Saito T. Clinical utility of antibiotic-loaded hydroxyapatite block for treatment of intractable periprosthetic joint infection and septic arthritis of the hip. Modern rheumatology 2015. link
2 papers cited of 3 indexed.